8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549


                                    FORM 8-K

                                 CURRENT REPORT


                     PURSUANT TO SECTION 13 OR 15(D) OF THE
                         SECURITIES EXCHANGE ACT OF 1934


                Date of Report (Date of earliest event reported)

                                  APRIL 7, 2004


                                  XTRANA, INC.
             (Exact name of registrant as specified in its charter)

          DELAWARE                    0-14257                    58-1729436
(State or other jurisdiction        (Commission                (IRS Employer
        of incorporation)           File Number)             Identification No.)


       590 BURBANK STREET, SUITE 205, BROOMFIELD, COLORADO         80020
             (Address of principal executive offices)           (Zip Code)


       Registrant's telephone number, including area code: (303) 466-4424





ITEM 5. - OTHER EVENTS AND REGULATION FD DISCLOSURE

         On April 7, 2004,  Xtrana,  Inc. (the "Company") issued a press release
announcing  stockholder  approval  of the  sale  of the  Company's  intellectual
property  to the  Applied  Biosystems  Group of Applera  Corporation.  The press
release  also  announced  that  Applied  Biosystems  had  delivered a $3,500,000
closing cash payment,  and the Company had delivered its  intellectual  property
rights,  into an escrow account pending the final closing of the transaction.  A
copy of the press  release is attached  to this Form 8-K as Exhibit  99.1 and is
incorporated herein by reference.


ITEM 7. - FINANCIAL STATEMENTS AND EXHIBITS

         (a)      Financial Statements.

                  None.

         (b)      Pro Forma Financial Information.

                  None.

         (c)      Exhibits.

                  99.1       Press release dated April 7, 2004


                                       2



                                   SIGNATURES

            Pursuant to the requirements of the Securities Exchange Act of 1934,
the  registrant  has duly  caused  this report to be signed on its behalf by the
undersigned hereunto duly authorized.


April 9, 2004                 XTRANA, INC.


                               /S/ JAMES H. CHAMBERLAIN
                              --------------------------------
                              James H. Chamberlain,
                              Chief Executive Officer


                                       3



                                  EXHIBIT INDEX


EXHIBIT NUMBER         DESCRIPTION

    99.1               Press release dated April 7, 2004


                                       4

EX-99

EXHIBIT 99.1

                                                        [GRAPHIC OMITTED] XTRANA

FOR IMMEDIATE RELEASE

                    XTRANA ANNOUNCES STOCKHOLDER APPROVAL OF
                        THE SALE OF ITS PATENT PORTFOLIO

Broomfield,  CO - April 7, 2004 -- XTRANA,  Inc.  (OTCBB:  XTRN) announced today
that  its  stockholders  have  approved  the  previously  announced  sale of its
intellectual  property to the Applied  Biosystems  Group of Applera  Corporation
(NYSE:   ABI)  for  $4,000,000  in  cash.  Xtrana  held  a  Special  Meeting  of
Stockholders on March 24, 2004, at which 9,907,956 shares were voted in favor of
the  intellectual  property  sale and  357,960  shares  were voted  against  the
proposal (with 35,940 shares abstaining).

Under  the  terms  of the  definitive  agreement  for the  transaction,  Applied
Biosystems  has agreed to purchase all  intellectual  property of Xtrana,  other
than  trademarks  and trade  names.  These  assets  include all U.S. and foreign
patents,  inventions,  trade secrets and know-how, and constitute  substantially
all of the assets of Xtrana. The total  consideration of $4,000,000 consists of:
(a) $100,000 in cash as a deposit,  which has already  been paid to Xtrana,  (b)
$3,500,000  in cash to be paid at closing;  and (c)  $400,000 in cash to be paid
ninety (90) days after closing,  subject to Xtrana providing certain  consulting
services as defined in the definitive agreement.

On March 31, 2004,  Applied  Biosystems  delivered the  $3,500,000  closing cash
payment,  and Xtrana delivered its intellectual  property rights, into an escrow
account  pending the final  closing of the  transaction.  Such closing will take
place after Applied  Biosystems'  receipt of certain  certifications from Xtrana
required  as part  of  Applied  Biosystems'  due  diligence  efforts  under  the
definitive  transaction  agreement.  While Xtrana  expects the final  closing to
occur within the next 30 days,  there can be no assurance  that the closing will
occur in a timely manner, if at all.

James Chamberlain, Xtrana's Interim CEO commented, "We are pleased that Xtrana's
stockholders  overwhelmingly  supported the transaction with Applied Biosystems.
Following  the  transaction,  we intend to explore  potential  transactions  for
merging or  otherwise  joining  together  with an existing  business  that could
create  long-term  stockholder  value.  After  closing  the  Applied  Biosystems
transaction, it is the intention of the Board of Directors to spend a reasonable
period of time exploring opportunities to find a merger candidate,  and if it is
unable to  conclude a  transaction  that it  believes  would  provide  long term
stockholder value, to propose that the stockholders approve a liquidation."

Xtrana,  Inc.  develops,  manufactures and markets novel nucleic acid extraction
kits and detection  systems for use in molecular  diagnostics,  drug  discovery,
forensics, research, clinical and life sciences markets.





This Press Release contains forward-looking  statements (identified by the words
"estimate,"  "anticipate," "expect," "believe," and similar expressions),  which
are based upon management's  current  expectations and speak only as of the date
made. These forward-looking  statements are subject to risks,  uncertainties and
factors that could cause actual  results to differ  materially  from the results
anticipated in the forward-looking  statements and include,  but are not limited
to, the ability to close the Applied Biosystems  transaction in a timely manner,
government regulations and rights with respect to the intellectual property sold
to Applied Biosystems, our ability to settle our remaining obligations following
the sale of our intellectual  property, our ability to find a merger partner, as
well as other factors discussed in our last Report on Form 10-KSB.

CONTACT:    Dennis Lineberry
            Vice President, Finance
            Xtrana, Inc.
            (303) 466-4424


                                       2